In the present study, we found that patients in the PD-pRBD+ group exhibited more severe motor and cognitive deficits, as well as significantly greater DAT loss compared to those in the PD-pRBD− group with comparable disease duration. This evidence concerns the gene SLC6A3 and Parkinson disease.